Guardant Health Inc (NASDAQ:GH) shares hit a new 52-week high during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $74.82 and last traded at $74.00, with a volume of 973532 shares traded. The stock had previously closed at $66.82.

The company reported ($0.30) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.05. The firm had revenue of $32.87 million for the quarter, compared to the consensus estimate of $24.57 million.

Several brokerages recently commented on GH. JPMorgan Chase & Co. upped their target price on Guardant Health from $42.00 to $85.00 and gave the company an “overweight” rating in a report on Wednesday. William Blair reiterated an “outperform” rating on shares of Guardant Health in a report on Wednesday. Finally, Bank of America reiterated a “neutral” rating and issued a $60.00 target price (up from $42.00) on shares of Guardant Health in a report on Thursday, February 28th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $72.50.

In related news, major shareholder Vision Fund (Aiv M1) Softbank bought 2,033,990 shares of Guardant Health stock in a transaction that occurred on Tuesday, March 12th. The shares were acquired at an average cost of $9.83 per share, for a total transaction of $19,994,121.70. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional investors have recently bought and sold shares of the business. Jennison Associates LLC bought a new position in shares of Guardant Health during the 4th quarter worth approximately $31,700,000. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Guardant Health during the fourth quarter worth approximately $26,000. TD Asset Management Inc. acquired a new position in shares of Guardant Health during the fourth quarter worth approximately $765,000. Kornitzer Capital Management Inc. KS acquired a new position in shares of Guardant Health during the fourth quarter worth approximately $2,096,000. Finally, Brandywine Managers LLC acquired a new position in shares of Guardant Health during the fourth quarter worth approximately $267,000. Hedge funds and other institutional investors own 69.54% of the company’s stock.

The stock has a market capitalization of $6.35 billion and a price-to-earnings ratio of -34.83.

TRADEMARK VIOLATION WARNING: “Guardant Health (GH) Reaches New 1-Year High on Strong Earnings” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2019/03/14/guardant-health-gh-reaches-new-1-year-high-on-strong-earnings.html.

Guardant Health Company Profile (NASDAQ:GH)

Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.

Featured Story: What is the downside to momentum investing?

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.